High expression levels of HMGA2 in patients with AML are related to a lower frequency of complete remission (about 59% vs. 83%), relapse-free survival (about 11% vs. 44%), and a poor 3-year overall survival (OS) (13.2% vs. 43%) [162]. Here, HMGA2 is linked to acute myeloid leukemia.